Literature DB >> 18199741

Reproducibility of QuantiFERON-TB gold in-tube assay.

Sharon Perry1, Luz Sanchez, Shufang Yang, Zubin Agarwal, Philip Hurst, Julie Parsonnet.   

Abstract

Studies are needed to characterize the reproducibility of QuantiFERON-TB Gold (QFT-G) for targeted U.S. screening populations. Members of northern California households were tested with the QFT-G in-tube assay (QFT-G-IT) at two home visits 3 months apart. Reproducibility and agreement with the tuberculin skin test (TST) were assessed. Monte Carlo simulation was used to evaluate the role of test-related error. Of 63 individuals (49 adults and 14 children) completing QFT-G-IT at both time points, 79% were foreign-born (98% from Latin America) and 68% reported Mycobacterium bovis BCG vaccination. At the baseline visit, 23 (37%) were TST positive and 15 (24%) were QFT-G-IT positive (kappa = 0.48 [+/- 0.11]). At 3 months, 3/48 (6.3%; 95% confidence interval [95CI], 2 to 17) of those initially QFT-G-IT negative converted, and 5/15 (33%; 95CI, 15 to 58) of those initially QFT-G-IT positive reverted. Among the 8 individuals with inconsistent QFT-G-IT results, the maximum gamma interferon response at either visit was 0.68 IU/ml versus means of 4.99 (+/- 3.74) and 6.95 (+/- 5.6) for 10 persistent positives at the first and second visits, respectively. Expected false-reversion and -conversion rates were 32% (90CI, 25 to 39%) and 6.95% (90CI, 4.6 to 9.8%) when the sensitivity and specificity were assumed to average 70% and 98%, respectively. Transient responses to QFT-G-IT are common, and low positive results need to be interpreted with caution. Further studies are needed to characterize the predictive value of the test for U.S. foreign-born and other targeted screening populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199741      PMCID: PMC2268272          DOI: 10.1128/CVI.00398-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  38 in total

1.  Commentary: H. pylori infection in early life and the problem of imperfect tests.

Authors:  Sharon Perry; Julie Parsonnet
Journal:  Int J Epidemiol       Date:  2005-11-22       Impact factor: 7.196

2.  QuantiFERON-TB predicts tuberculin skin test boosting in U.S. foreign-born.

Authors:  M Nguyen; S Perry; J Parsonnet
Journal:  Int J Tuberc Lung Dis       Date:  2005-09       Impact factor: 2.373

3.  Comparison of mantoux skin test with three generations of a whole blood IFN-gamma assay for tuberculosis infection.

Authors:  H Mahomed; E J Hughes; T Hawkridge; D Minnies; E Simon; F Little; W A Hanekom; L Geiter; G D Hussey
Journal:  Int J Tuberc Lung Dis       Date:  2006-03       Impact factor: 2.373

Review 4.  Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion.

Authors:  D Menzies
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

5.  Comparison of a new ESAT-6/CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population.

Authors:  Emaeil Porsa; Lee Cheng; Michael M Seale; George L Delclos; Xin Ma; Robert Reich; James M Musser; Edward A Graviss
Journal:  Clin Vaccine Immunol       Date:  2006-01

6.  Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.

Authors:  Gerald H Mazurek; John Jereb; Phillip Lobue; Michael F Iademarco; Beverly Metchock; Andrew Vernon
Journal:  MMWR Recomm Rep       Date:  2005-12-16

7.  Evaluation of the tuberculin gamma interferon assay: potential to replace the Mantoux skin test.

Authors:  S Pottumarthy; A J Morris; A C Harrison; V C Wells
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

8.  Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country.

Authors:  Young Ae Kang; Hye Won Lee; Ho Il Yoon; BeLong Cho; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  JAMA       Date:  2005-06-08       Impact factor: 56.272

9.  Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis.

Authors:  Abebech Demissie; Eliane M S Leyten; Markos Abebe; Liya Wassie; Abraham Aseffa; Getahun Abate; Helen Fletcher; Patrick Owiafe; Philip C Hill; Roger Brookes; Graham Rook; Alimuddin Zumla; Sandra M Arend; Michel Klein; Tom H M Ottenhoff; Peter Andersen; T Mark Doherty
Journal:  Clin Vaccine Immunol       Date:  2006-02

10.  Identifying ELISPOT and skin test cut-offs for diagnosis of Mycobacterium tuberculosis infection in The Gambia.

Authors:  D J Jeffries; P C Hill; A Fox; M Lugos; D J Jackson-Sillah; R A Adegbola; R H Brookes
Journal:  Int J Tuberc Lung Dis       Date:  2006-02       Impact factor: 2.373

View more
  35 in total

1.  Use of interferon-gamma release assays in a health care worker screening program: experience from a tertiary care centre in the United States.

Authors:  Manish Joshi; Thomas P Monson; Gail L Woods
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

2.  Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: dynamic patterns and interpretational challenges.

Authors:  Madkuhar Pai; Kevin Elwood
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

3.  Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection.

Authors:  David Doberne; Rajiv L Gaur; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2011-06-22       Impact factor: 5.948

4.  Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses in German health care workers.

Authors:  Felix C Ringshausen; Albert Nienhaus; José Torres Costa; Heiko Knoop; Stephan Schlösser; Gerhard Schultze-Werninghaus; Gernot Rohde
Journal:  Clin Vaccine Immunol       Date:  2011-05-18

5.  Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country.

Authors:  Anne M Dyrhol-Riise; Gerd Gran; Tore Wentzel-Larsen; Bjørn Blomberg; Christel Gill Haanshuus; Odd Mørkve
Journal:  BMC Infect Dis       Date:  2010-03-08       Impact factor: 3.090

6.  Serial testing with an interferon-γ release assay in German healthcare workers.

Authors:  Anja Schablon; Melanie Harling; Roland Diel; Felix C Ringshausen; Jose Torres Costa; Albert Nienhaus
Journal:  GMS Krankenhhyg Interdiszip       Date:  2010-09-21

7.  Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers.

Authors:  Felix C Ringshausen; Albert Nienhaus; Anja Schablon; Stephan Schlösser; Gerhard Schultze-Werninghaus; Gernot Rohde
Journal:  BMC Infect Dis       Date:  2010-07-23       Impact factor: 3.090

8.  High prevalence of latent tuberculosis infection among injection drug users in Tijuana, Mexico.

Authors:  R S Garfein; R Lozada; L Liu; R Laniado-Laborin; T C Rodwell; R Deiss; J Alvelais; A Catanzaro; P G Chiles; S A Strathdee
Journal:  Int J Tuberc Lung Dis       Date:  2009-05       Impact factor: 2.373

Review 9.  Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review.

Authors:  Richard N van Zyl-Smit; Alice Zwerling; Keertan Dheda; Madhukar Pai
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

10.  Infection with Helicobacter pylori is associated with protection against tuberculosis.

Authors:  Sharon Perry; Bouke C de Jong; Jay V Solnick; Maria de la Luz Sanchez; Shufang Yang; Philana Ling Lin; Lori M Hansen; Najeeha Talat; Philip C Hill; Rabia Hussain; Richard A Adegbola; Joanne Flynn; Don Canfield; Julie Parsonnet
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.